About Spotitearly
Spotitearly is a company based in Tel Aviv (Israel) founded in 2020 by Ohad Sharon. Spotitearly has raised $6.21 million across 2 funding rounds from investors including Hanaco Ventures, Jeff Schwartz and Michael Eisenberg. Spotitearly offers products and services including Cancer Pre-Screening, BRCA Germline, Bio-Hybrid Platform, and Bio-Sensors. Spotitearly operates in a competitive market with competitors including Panakeia, Boston Medical Sciences, Nevia Bio, SquareMind and Onkolyze, among others.
- Headquarter Tel Aviv, Israel
- Founders Ohad Sharon
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$6.21 M (USD)
in 2 rounds
-
Latest Funding Round
$10 K (USD), Seed
Jul 21, 2025
-
Investors
Hanaco Ventures
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Spotitearly
Spotitearly offers a comprehensive portfolio of products and services, including Cancer Pre-Screening, BRCA Germline, Bio-Hybrid Platform, and Bio-Sensors.
Breath-based at-home test for early detection of multiple cancers.
Test for inherited gene mutations linked to cancer risks.
Integrates biosensors and AI for breath sample analysis.
Devices that identify cancer-related compounds in breath.
People of Spotitearly
Unlock access to complete
Unlock access to complete
Funding Insights of Spotitearly
Spotitearly has successfully raised a total of $6.21M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $10 thousand completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Spotitearly
Spotitearly has secured backing from 3 investors, including venture fund and angel investors. Prominent investors backing the company include Hanaco Ventures, Jeff Schwartz and Michael Eisenberg.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Startups are funded through venture capital by Hanaco Ventures.
|
Locked | Locked | Locked | |
|
JS
Jeff Schwartz |
Angel investor in Indian startups, focused on tech and innovation.
|
Locked | Locked | Locked |
|
ME
Michael Eisenberg |
-
|
Locked | Locked | Locked |
Investor details for Spotitearly
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Spotitearly
Investment portfolio details for Spotitearly
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Spotitearly
Detailed financials for Spotitearly
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Spotitearly Comparisons
Peer comparison for Spotitearly
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Spotitearly
Spotitearly operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Panakeia, Boston Medical Sciences, Nevia Bio, SquareMind and Onkolyze, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-based software is provided for cancer diagnosis and precision treatment.
|
|
| Locked | Locked | Locked |
AI-powered colorectal cancer screening system
|
|
| Locked | Locked | Locked |
Machine learning-enabled platform for early detection of women-related diseases
|
|
| Locked | Locked | Locked |
Developer of robotic medical equipment for skin cancer detection
|
|
| Locked | Locked | Locked |
Ultrasound images are analyzed by AI platform for cancer detection.
|
|
| Locked | Locked | Locked |
Portable digital device for cervical exams, risk assessment, and telemedicine integration.
|
Detailed competitors of Spotitearly
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Spotitearly
Complete news archive for Spotitearly
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Spotitearly
Spotitearly was founded in 2020 and raised its 1st funding round 2 years after it was founded.
Spotitearly is headquartered in Tel Aviv, Israel.
Spotitearly is a funded company, having raised a total of $6.21M across 2 funding rounds to date.
AI-based cancer detection device for providers. The company has developed a screening test mask that can be used for screening different stages and kinds of cancer based on its odor. It has features for real-time analysis, an AI system for detection, and more.
Spotitearly's top competitors include Inocras, Panakeia and Boston Medical Sciences.
Spotitearly offers Cancer Pre-Screening, BRCA Germline, Bio-Hybrid Platform, and Bio-Sensors.
Spotitearly has 3 investors. Key investors include Hanaco Ventures, Jeff Schwartz, and Michael Eisenberg.